Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus CLINDAMYCIN HYDROCHLORIDE.
CLEOCIN HYDROCHLORIDE vs CLINDAMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Binds to the 50S ribosomal subunit, inhibiting peptide bond formation and bacterial protein synthesis.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
150-450 mg orally every 6 hours; maximum 1.8 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
The terminal elimination half-life of clindamycin is approximately 2-3 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life is prolonged to 8-12 hours. Renal impairment does not significantly alter half-life.
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Approximately 10-20% of clindamycin is excreted unchanged in urine; the remainder is hepatically metabolized and excreted in bile and feces as inactive metabolites. Fecal excretion accounts for about 4% of an administered dose as active drug and 60-70% as metabolites. Renal clearance is minor.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic